Clinical study of transcriptome high-throughput sequencing and targeted therapy in children with relapsed or refractory acute myeloid leukemia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000037553

Enrollment

Unknown

Registered

2020-08-28

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed or refractory acute myeloid leukemia

Interventions

Case series:DEC+CLAG +/- target treatment

Eligibility

Sex/Gender

All

Age

0.5 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Relapsed or refractory AML included granulocytic sarcoma and MDS-RAEBT; 2. aged <= 18 years old; 3. Obtain the consent of the guardian or and patient, and sign on the informed consent form; 4. The estimated survival time was more than 3 months.

Exclusion criteria

Exclusion criteria: 1. Juvenile myelomonocytic leukemia (JMML); 2. AML secondary to Fanconi anemia (FA); 3. AML secondary to Down syndrome; 4. AML secondary to any other congenital disease; 5. only temporary chemotherapy, radiotherapy or immunotherapy, but not systematic treatment according to the treatment plan; 6. Coexisting diseases or mental diseases with any significant abnormality affect the life safety and compliance of patients. 7. Patients with poor nutritional status, severe infection, cardiac insufficiency, and unable to tolerate chemotherapyts with poor nutritional status, severe infection, cardiac insufficiency, and unable to tolerate chemotherapy.

Design outcomes

Primary

Measure	Time frame
remission rate;overall survive;	—

Secondary

Measure	Time frame
mutate gene;MRD;	—

Countries

China

Contacts

Public ContactNa Zhang

Shanghai Children's Hospital

abczhangna@hotmail.com+86 18101887300

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026